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Abstract
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to
infect neighboring hepatocytes. Viral cell-cell transmission has been shown to play an important role in viral persistence
allowing evasion from neutralizing antibodies. In contrast, the role of HCV cell-cell transmission for antiviral resistance is
unknown. Aiming to address this question we investigated the phenotype of HCV strains exhibiting resistance to direct-
acting antivirals (DAAs) in state-of-the-art model systems for cell-cell transmission and spread. Using HCV genotype 2 as a
model virus, we show that cell-cell transmission is the main route of viral spread of DAA-resistant HCV. Cell-cell transmission
of DAA-resistant viruses results in viral persistence and thus hampers viral eradication. We also show that blocking cell-cell
transmission using host-targeting entry inhibitors (HTEIs) was highly effective in inhibiting viral dissemination of resistant
genotype 2 viruses. Combining HTEIs with DAAs prevented antiviral resistance and led to rapid elimination of the virus in
cell culture model. In conclusion, our work provides evidence that cell-cell transmission plays an important role in
dissemination and maintenance of resistant variants in cell culture models. Blocking virus cell-cell transmission prevents
emergence of drug resistance in persistent viral infection including resistance to HCV DAAs.
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Introduction
There is accumulating evidence that viruses use different routes
for transmission and spread in infected tissue [1,2]. A well-
characterized example is hepatitis C virus (HCV) that is
transmitted between hepatocytes via classical cell entry using
cell-free diffusion but also uses direct cell-cell transfer to infect
neighboring cells [3,4] (Figure 1A). While cell-free entry is most
appropriate for the initiation of HCV infection, cell-cell transmis-
sion is thought to play an important role in viral persistence and in
the maintenance of infection [5]. A key feature of cell-cell
transmission is its resistance to neutralizing antibodies present in
HCV-infected individuals [4].
Several host factors involved in cell-free viral entry have also
been shown to contribute to cell-cell transmission. These include
scavenger receptor BI (SR-BI), CD81, tight junction proteins
claudin-1 (CLDN1) and occludin (OCLN) as well as host cell
kinase epidermal growth factor receptor (EGFR) and its signal
transducer HRas [6–12]. HCV envelope glycoproteins are also
essential for this process [11]. However, whereas the majority of
monoclonal antibodies (mAbs) targeting the viral envelope fails to
inhibit cell-cell transmission, several host-targeting entry inhibitors
(HTEIs) have been shown to inhibit HCV cell-cell transmission
[6–12].
Antiviral resistance remains a major challenge for the treatment
of chronic viral infections including HCV, hepatitis B virus (HBV),
human immunodeficiency virus (HIV) and influenza infection.
Antiviral resistance to nucleos(t)ide analogs is a major cause of
treatment failure in chronic HBV-infected patients [13]. Although
the combination of antiretroviral drugs has markedly improved the
effective control of the progression of HIV disease, the emergence
of multidrug-resistant viruses still threatens their long-term efficacy
[14]. The recent introduction of a first-generation protease
inhibitor to pegylated interferon-alfa/ribavirin (PEG-IFN-a/
RBV) therapy has improved the outcome for HCV genotype 1-
infected patients [15,16], but a main limitation of these
PLOS Pathogens | www.plospathogens.org 1 May 2014 | Volume 10 | Issue 5 | e1004128direct-acting antivirals (DAAs) is their low genetic barrier for
resistance [17,18]. Next generation viral protease inhibitors, NS5A
and polymerase inhibitors are currently being evaluated in
combination with PEG-IFN-a or other DAAs in IFN-free
regimens, with or without RBV [19–26] with sofosbuvir and
simeprevir having received FDA approval. Although newly
developed DAAs are very effective in the majority of previously
untreated patients, antiviral resistance as well as differences in
virological outcomes for different genotypes and subtypes have
been reported [24,27,28]. Furthermore, a significant number of
patients with advanced liver disease and who are null or partial
responders to previous therapy still do not achieve a sustained
virological response [18,22,26,29].
The functional role of cell-cell transmission and spread in the
emergence of antiviral resistance is unknown. The aim of this study
was to assess the role of cell-cell transmission in antiviral resistance
using HCV genotype 2 infection as a model, and to explore cell-cell
transmission as a target to prevent and treat DAA-resistance.
Materials and Methods
Cell lines
Culture of Huh7.5.1 [30], Huh7.5-GFP [11] and CD81
2
Huh7.5 cells [31] has been described.
Antibodies and inhibitors
CLDN1- (OM-7D3-B3) [32], SR-BI- (NK-8H5-E3) [8] and
CD81- (QV-6A8-F2C4) [9] specific mAbs and respective control
mAbs have been described. Erlotinib was obtained from LC
Laboratories. Anti-HCV neutralizing antibodies (AP33 from
Genentech and purified human anti-HCV IgG from our labora-
tory) have been described [33,34]. Mouse/human IgG was from
BD Bioscience and NS5A-specific mouse mAb was from Virostat.
The E2-specific human antibody (CBH-23) was a kind gift from Dr.
Steven Foung (Stanford University, USA) [35]. Inhibitors of HCV
protease (telaprevir, boceprevir and simeprevir) and HCV NS5A
(daclatasvir) were synthesized by Acme Bioscience, Inc.
Primers
Primers used to generate NS3 mutations: 59-GTT GGG CTC
TTC CGA TCA GCT GTG TGC TCT C-39 (A156S, sense), 59-
GAG AGC ACA CAG CTG ATC GGA AGA GCC CAA C-39
(A156S, antisense), 59- CGG GGA AGT CCA AAT CAT GTC
CAC AGT CTC TCA-39 (L36M, sense), 59-TGA GAG ACT
GTG GAC ATG ATT TGG ACT TCC CCG-39 (L36M,
antisense), 59-CGT CGT TGG GCT CTT CAA AGC AGC
TGT GTG CTC T -39 (R155K, sense) and 59- AGA GCA CAC
AGC TGC TTT GAA GAG CCC AAC GAC G-39 (R155K,
antisense). Primers used in nested PCR for direct sequencing of
NS3 mutations: NS3 outer forward, 59-ATC GTC TGG GGA
GCG GAG AC-39; NS3 outer reverse, 59-AAT TTG CCA TAT
GTG GAG TAC GT-39; NS3 inner forward, 59-ACG GCT GCA
TGT GGG GAC AT-39; NS3 inner reverse, 59-GTG CTC TTT
CCA CTG GT-39. Primers used for amplifying and sequencing
E1E2 mutations: 59-TTT GCC GAC CTC ATG GGG TAC AT-
39; reverse, 59-TCC GCT AAG AAG AGC AGG AAT AAG
AGT A-39. Primers used in nested PCR for amplifying NS5A
cDNA fragments: NS5A outer forward, 59-CTA CGT GAC GGA
GTC GGA TG-39; NS5A outer reverse, 59-AAC TTT TCC TCT
TCG GGG CT; NS5A inner forward, 59-CAG CGT GTG ACC
CAA CTA CT-39; NS5A inner reverse, 59-TCG GGG CTA CAG
GGA GTT AT-39. Primers used for sequencing NS5A region:
TAA CTG AGG ACT GCC CCA TCC CAT, TTA AGC CCA
ACG CAG AAC GA, CGC AGA CGT ATT GAG GTC CAT
GCT AA.
Production and infection of DAA-resistant cell-culture
derived HCV (HCVcc)
Drug-resistant individual or combined mutations were intro-
duced in the NS3 region of the Luc-Jc1 (genotype 2a/2a) and/or
Jc1 plasmid [36-38] using the QuikChange II XL site-directed
mutagenesis kit (Stratagene) as previously described [39]. A one-
step polymerase chain reaction (PCR) mutagenesis was performed
using the primers as described in ‘‘Primers’’. Mutations NS3-
A156S, NS3-R155K and NS3-L36M/R155K were confirmed by
DNA sequence analysis (GATC Biotech) for the desired mutation
and for exclusion of unexpected residue changes in the NS3
encoding sequences. HCVcc J4/JFH1 (genotype 1b/2a) and
HCVcc J4/JFH1 NS5A-Y93H (Y2065H) have been described
[40]. HCVcc (TCID50 10
3/mL to 10
4/mL) were produced as
described [6]. Viral infection was analyzed by assessing the
intracellular luciferase activity [6,32] or intracellular HCV RNA
levels as described [6,32,41].
HCV spread assay
Huh7.5.1 cells transfected with HCVcc Luc-Jc1 or Luc-Jc1
containing the NS3 A156S mutation were cultured with fresh
Huh7.5.1 cells (1:1) in 24-well plates. Medium was replenished
every 3–4 days until the end of the experiment. Cells were
harvested at different time points and HCV infection was assayed
in cell lysates by monitoring luciferase activity and the percentage
of infected cells was assessed by NS5A immunostaining with flow
cytometry over 14 days. To investigate the role of cell-cell
transmission for viral spread and dissemination, neutralizing
antibodies (nAbs, 25 mg/mL AP33 or 25 mg/mL anti-HCV IgG)
potently inhibiting cell-free entry [6,11] were added to block cell-
free transmission until the end of the experiment (Figure 1B).
HCV cell-cell transmission assay
Cell-cell transmission was assessed as illustrated in Figure 1C
and described previously [6,11]. Producer Huh7.5.1 cells were
Author Summary
In spite of the rapid development of antiviral agents,
antiviral resistance remains a challenge for the treatment
of viral infections including hepatitis B and C virus (HBV,
HCV), human immunodeficiency virus (HIV) and influenza.
Virus spreads from infected cells to surrounding uninfect-
ed host cells to develop infection through cell-free and
cell-cell transmission routes. Understanding the spread of
resistant virus is important for the development of novel
antiviral strategies to prevent and treat antiviral resistance.
Here, we characterize the spread of resistant viruses and its
impact for emergence and prevention of resistance using
HCV as a model system. Our results show that cell-cell
transmission is the main transmission route for antiviral
resistant HCV strains and is crucial for the maintenance of
infection. Monoclonal antibodies or small molecules
targeting HCV entry factors are effective in inhibiting the
spread of resistant HCV in cell culture models and thus
should be evaluated clinically for prevention and treat-
ment of HCV resistance. Combination of inhibitors target-
ing viral entry and clinically used direct-acting antivirals
(DAAs) prevents antiviral resistance and leads to viral
eradication in cell culture models. Collectively, the inves-
tigation provides a new strategy for prevention of viral
resistance to antiviral agents.
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resistant mutations and co-cultured with naive target Huh7.5-GFP
cells in the presence of 1 or 10 mg/mL CLDN1-specific mAb,
10 mM erlotinib, 10 mg/mL SR-BI-specific mAb or DMSO
solvent/rat IgG control. A well-described pool of anti-HCV nAbs
(anti-HCV IgG, 25 mg/mL) [34] was added to block cell-free
transmission. After 24 h of co-culture, cells were fixed with 1%
paraformaldehyde, stained with an NS5A-specific mouse antibody
(0.1 mg/mL) or an E2-specific human antibody (CBH-23, 1 mg/
mL) and analyzed by flow cytometry [6,11]. Dead cells and
doublets were excluded by scatter gating and cell doublets were
discriminated based on FSC-A and FSC-H parameters as
described [42]. Cell-cell transmission was defined as percentage
HCV infection of Huh7.5-GFP target cells in the presence of anti-
HCV neutralizing Abs.
Long-term HCV infection assay
Huh7.5.1 cells were electroporated with Jc1 RNA and seeded in
12-well plates (10
5 cells/well). Cells were treated with control
medium, CLDN1- or SR-BI-specific mAb (10 mg/mL), simeprevir
(500 nM), daclatasvir (5 nM), the combination of CLDN1- or SR-
BI-specific mAb and simeprevir or the combination of daclatasvir
and simeprevir. 1% DMSO medium was used during the whole
cultivation process to transition the cells into non-dividing stage as
described recently [43]. Media were replenished every 3–4 days
and HCV RNA was monitored by RT-PCR [44]. Absent HCV
RNA quantification by RT-PCR was confirmed using the Abbott
RealTime HCV assay (Abbott) (LOD 48 IU/mL with 250 mL
liquid sample).
Sequencing of HCV E1E2 envelope, NS3 protease and
NS5A mutations
5 mL of purified extracellular viral RNA, isolated and
purified using QIAamp Viral RNA Mini Kit (Qiagen), was
reverse-transcribed into cDNA (Thermo Scientific). HCV E1/
E2, NS3 and NS5A cDNA fragments were amplified by
nested PCR using the primers as described in ‘‘Primers’’.
The PCR products were then separated on a 1% agarose gel
and purified using Wizard SV Gel and PCR Clean-Up
System (Promega). The presence of predominant mutations was
analyzed by DNA direct sequence analysis (GATC Biotech) using
Chromas Pro Version 1.7.3 software (Technelysium Pty Ltd). To
further identify DAA-resistant mutations in the HCV NS3 gene,
the purified second round PCR products were ligated into a
pGEM-T vector (Promega) and then used to transform JM109
competent cells for clonal selection on LB/ampicillin/IPTG/X-
Gal plates according to the manufacturer’s protocol. Plasmid
DNA from selected clones was amplified and purified using a
Qiagen Miniprep Kit (Qiagen) for DNA sequencing (GATC
Biotech).
Cell viability assays
Cytotoxic effects on cells were assessed at the end of the long-
term HCV infection assay by analyzing the ability of the cells to
metabolize 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) as previously described [6].
Statistical analysis
Unless otherwise stated, results are expressed as means6stan-
dard deviation (SD) from at least 3 independent experiments
performed in triplicate. Statistical analyses were performed using
Student’s t-test, with a p-value of ,0.05 being considered
statistically significant.
Results
Cell-cell spread is the main route for transmission and
dissemination of DAA-resistant viruses
The spread of DAA-resistant viruses has an important impact
for the development of antiviral resistance, leading to viral
breakthrough and treatment failure. However, the role of viral
cell-cell transmission and spread for resistance is unknown. To
address this question, we first generated DAA-resistant viruses by
introducing well-characterized DAA-resistance mutations in NS3
(NS3-A156S, NS3-R155K and NS3-L36M/R155K) or NS5
region (NS5A-Y93H) [45]. Introduction of mutations increased
the IC50 of telaprevir, boceprevir and daclastavir up to 10-fold
(Figure S1 and Table S1), demonstrating that these DAA-resistant
viruses are indeed able to escape inhibition by DAAs.
We then investigated the spread of DAA-resistant viruses using
a recently developed state-of-the-art model for viral spread [6,8]
which is displayed in Figure 1B and described in Materials and
Methods. As shown in Figure 2A–B, both wild-type and DAA-
resistant (A156S) viruses efficiently spread during the first 14 days
after infection, despite the presence of anti-HCV nAb (AP33)
efficiently blocking viral entry through cell-free transmission, with
an increase of more than 2 log10 in their viral load. Sequence
analysis demonstrated that DAA-resistant virus (A156S) was
indeed the predominant variant at day 14 in the experiments
displayed in Figure 1B, D and F (data not shown). Thus, given an
inhibition of viral entry through cell-free transmission of more
than 95% in the presence of nAb (AP33) [6] (Figure 2G), we
conclude that cell-cell transmission represents the main transmis-
sion route for DAA-resistant viruses. We quantified the percentage
of HCV positive cells at the end of the viral spread assay (Figure 3).
The majority of the cells became HCV positive (96%/WT, 92%/
A156S) after 14 days of viral spread (Figure 3A–B). Although cell-
free HCV in the supernatant was efficiently neutralized by nAb
(anti-HCV IgG) (Figure 3C), the spread of wild-type and DAA-
resistant HCV was still efficient in the presence of nAb (86%/WT,
82%/A156S) (Figure 3A–B). Given the minor effect of nAbs
Figure 1. Cell culture model systems for analysis of HCV dissemination and cell-cell transmission. (A) Transmission pathways of HCV.
HCV can disseminate through two routes of transmission: cell-free entry and cell-cell transmission. Cell-free entry is the classical pathway for initiation
of HCV infection and requires a well-defined panel of host entry factors including SR-BI, CD81, CLDN1, OCLN and the EGFR signaling pathway [6-
10,12]. Cell-free entry does not require cell-cell contact and is efficiently inhibited by neutralizing antibodies (nAbs). Cell-cell transmission requires
direct cell-cell contact and is resistant to nAbs present in HCV-infected patients. Cell-cell transmission is considered to play a key role for viral spread
and maintenance of infection [4,31]. (B) HCV spread and dissemination assay. The HCV spread assay monitors viral spread in cell cultures using a low
number of Huh7.5.1 cells containing replicating HCVcc, which expand over a time period of 14 days [6,8]. In the absence of nAb or presence of
control antibody the virus is transmitted by cell-cell and cell-free spread (upper panel [6,8]). Cell-free transmission can be blocked by anti-HCV nAbs
allowing to study viral spread mediated by cell-cell transmission only (lower panel). (C) HCV cell-cell transmission assay [6,7,11]. The cell-cell
transmission assay allows the investigation of cell-cell transmission and its inhibition by HTEIs. In this assay HCV
+ Huh7.5.1 producer cells containing
replicating HCVcc (stained by an anti-NS5A antibody and indicated in red) are co-cultured with HCV
2 Huh7.5 GFP target cells (indicated in green) for
24 h in the presence of nAb blocking cell-free transmission. Flow cytometry is used to quantitate infected HCV
+ Huh7.5 GFP target cells (indicated by
red and green), which are infected via cell-cell transmission and stained with anti-NS5A antibody.
doi:10.1371/journal.ppat.1004128.g001
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cell-cell transmission is the major route of viral dissemination for
both wild-type and DAA-resistant HCV.
HTEIs efficiently block cell-cell spread of DAA-resistant
HCV
We next investigated whether HTEIs inhibit total spread of
DAA-resistant viruses. As shown in Figure 2C-F and Figure 3A–B,
in contrast to telaprevir, which did not inhibit viral spread of the
DAA-resistant virus, HTEIs such as CLDN1-specific mAb and
erlotinib markedly inhibited viral spread of wild-type and DAA-
resistant viruses. Collectively, these data demonstrate that blocking
the spread of DAA-resistant viruses by HTEIs is useful to prevent
viral breakthrough caused by DAA resistance (Figures 2C–F, 3A–
B, S2, S3 and Table 1).
To confirm that HTEIs inhibit viral spread by inhibition of cell-
cell transmission of DAA-resistant HCV, we applied a well-
established cell-cell transmission assay (Figure 1C). In this assay
HCV producer cells are co-cultured with HCV target cells for
24 h in the presence of broadly nAbs (anti-HCV IgG) [6,8] to
inhibit cell-free viral entry. Since anti-HCV IgG inhibited up to
95% of HCV cell-free entry (Figure 2G and 3C), viral transmission
thus occurs predominantly via cell-cell transfer in this assay. As
shown in Figure 4A and 4C (left panels), HCVcc Jc1(2a/2a) NS3-
A156S and Jc1(2a/2a) NS3-L36M/R155K are indeed efficiently
transmitted through cell-cell transmission, and the extent of their
spread through this route was similar to the wild-type strain (data
not shown) [6,8], demonstrating that DAA-resistant HCVcc are
transmitted through cell-cell transfer and thus escape circulating
neutralizing antibodies. CLDN1-specific mAb and erlotinib
markedly inhibited cell-cell transmission of protease inhibitor-
resistant viruses (Figure 4). J4/JFH1 NS5A (1b/2a) is hundreds of
times less infectious than Jc1 [46], resulting in less efficient viral
cell-cell transmission than Jc1 NS3-A156S and NS3-L36K/
R155K (Figure S4). Although cell-cell transmission for this strain
was very low, the HTEIs appeared also to have a potential
inhibitory effect on cell-cell transmission of NS5A inhibitor-
resistant viruses (Figure S4). These results demonstrate that HTEIs
prevent cell-cell transmission of DAA-resistant viruses in cell
culture models.
Viral spread through HCV host entry factors is essential
for maintenance of persistent viral infection
Interestingly, in Figure 2E–F, the HTEIs (CLDN1-specific mAb
and erlotinib) not only inhibited viral spread, but also were capable
of decreasing viral load 7 days after treatment with HTEIs,
suggesting that blocking HCV cell-cell transmission impairs
maintenance of HCV infection. To further test this hypothesis,
we monitored HCV infection in CD81 knock-out hepatoma cells
(CD81
2Huh7.5) that are resistant to cell-free entry and only
display minimal levels of CD81-independent cell-cell transmission
[11,31]. Briefly, we transfected CD81
2Huh7.5 cells with HCV
RNA (Luc-Jc1) and monitored HCV infection in the viral spread
assay over 2 weeks. Consistent with the results shown in Figure 2E–
F, HCV load in CD81
2Huh7.5 cells gradually decreased, while it
increased over 30 times in control CD81-expressing Huh7.5 cells
(Figure 2H). Collectively these results indicate that cell-cell viral
spread is essential for maintenance of persistent HCV infection in
cell culture models.
Inhibition of cell-cell transmission by HTEIs prevents
emergence of DAA-resistant variants and results in viral
clearance
To assess whether blocking cell-cell transmission of DAA-
resistant variants by HTEIs impairs the emergence of viral
resistance in cell culture models we established long-term HCV
infection experiments using HCV-Jc1 transfected Huh7.5.1 cells
incubated in the presence of DMSO [43,47]. The incubation of
cells in the presence of DMSO has been shown to allow studying
virus-host interactions during long-term infection and has been
suggested to be one of the most physiological HCV cell culture
models based on liver-derived cell lines [43,47].
We chose a well-characterized protease inhibitor, simeprevir,
which has recently received FDA approval to treat chronic
hepatitis C, for further studies. Approximately 60% of the cells
stained HCV-positive before initiation of treatment (Figure S5). It
has been shown that simeprevir efficiently inhibits HCV replica-
tion in HCV cell culture with IC50 being below 13 nM [48]. We
used a dose of 500 nM (.IC90), which reduced viral load more
than 10-fold within 3 days in HCV cell culture confirming that the
dose is highly potent and relevant for inhibition of genotype 2
replication (Figure 5A). As shown in Figure 5A, simeprevir
treatment resulted in a rapid decline of the viral load initially,
reducing the viral load of HCV-infected cells by up to 1.5 log10
within 5–6 days after introducing the DAA. However, viral
rebound was observed after 2–3 weeks, with a viral load increasing
to the same level as untreated cells in line with previous reports
[48].
In contrast, treatment using an HTEI such as CLDN1-
specific mAb (OM-7D3-B3), which has been shown to inhibit
HCV entry in a pan-genotypic activity without displaying any
cytotoxic effect on hepatic cells [32], led to a slow but steady
decrease of the viral load (Figure 5A). No viral rebound was
observed during CLDN1-specific mAb treatment, demonstrat-
ing that CLDN1 as a target has a high genetic barrier to HCV
resistance. Finally, combination of CLDN1-specific mAb and
simeprevir resulted in a more rapid, efficient and sustained
reduction in viral load than simeprevir monoexposure
(Figure 5A). Most interestingly, during combination treatment,
HCV RNA became undetectable by qualitative RT-PCR and
using the clinically licensed Abbott RealTime HCV assay
(Abbott) with a limit of detection of 48 IU/mL (Figure 5A).
Viral load remained undetectable after withdrawal of the
combination treatment, indicating that viral eradication was
sustained and indeed due to the combination of entry and
Figure 2. The spread of DAA-resistant viruses is resistant to neutralizing antibodies against HCV but is efficiently inhibited by
HTEIs. (A–F) DAA-resistant variant (Luc-Jc1 A156S in (B), (D) and (F)) or wild-type HCVcc (Luc-Jc1 in (A), (C) and (E)) transfected Huh7.5.1 cells and
uninfected Huh7.5.1 cells were incubated in the presence of isotype control antibody (mouse IgG, 25 mg/mL) (total transmission) (A–B), anti-HCV
neutralizing antibody (anti-E2 mAb, AP33, 25 mg/mL) to block cell-free transmission (cell-cell transmission) (A–B), 1 mM of telaprevir (C–D), 10 mg/mL
of anti-CLDN1 mAb (E–F) or 10 mM of erlotinib (E–F) 2-3 days after transfection. Different media were replenished every 3–4 days. HCV infection was
measured by luciferase reporter gene expression in cell lysates at indicated time points as described [36]. (G) HCVcc (Luc-Jc1) was preincubated with
cell culture medium (mock control) or control IgG (25 mg/ml) or nAb (AP33 or anti-HCV IgG, 25 mg/ml) for 1 h and then incubated with Huh7.5.1 cells
for 4 h at 37uC. HCV load was analyzed 72 h post-infection by luciferase activity. (H) CD81
2Huh7.5 cells or Huh7.5 cells were transfected with HCV
Luc-Jc1 and maintained in cell culture over 2 weeks. The intracellular viral load was monitored by measuring luciferase activity every 2–4 days. Means
6 SD from at least three independent experiments performed in triplicate are shown.
doi:10.1371/journal.ppat.1004128.g002
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and reports from others, anti-CLDN1 mAb and simeprevir
exhibit no toxicity to hepatoma cells in vitro at the concentra-
tions used in this study [32,48]. Nevertheless, we performed
additional experiments to exclude that toxic effects were
responsible for decline in viral load and loss of virus. As shown
in Table 2, MTT-based cell viability assays at the end of the
long-term experiments showed no differences between treated
and untreated cells. These data confirm that the clearance of
viral infection is indeed due to HTEI treatment and not related
to adverse effects of the compounds during long-term
treatment.
To further explore the development of viral resistance, we
performed sequence analyses of viral variants at different time
points (the start of treatment, 10 and 23 days after treatment).
Whereas DAA-monotherapy resulted in the emergence of well-
described NS3 resistance mutations 23 days after treatment
(Figure 6 and 7), wild-type NS3 HCV remained the predominant
strain in CLDN1-specific mAb alone as well as in combination of
CLDN1-specific mAb and simeprevir treated cells. Although
sequence analyses revealed some rarely occurring variants
associated with low DAA resistance (e.g. NS3 I170T) in the
presence of combination of CLDN1-specific mAb and simeprevir,
these variants were cleared at the end of the treatment as
indicated by undetectable viral RNA (Figure 5A). These results
demonstrate that the HTEI functionally prevents antiviral
Figure 3. Cell-cell transmission is the main transmission route for DAA-resistant viruses. The spread assay was performed as shown in
Figure 2 with or without 25 mg/mL anti-HCV IgG to neutralize cell-free transmission of virus. The relative percentage HCV-positive cells/total cells was
determined by immunostaining for NS5A and flow cytometry. Huh7.5.1 uninfected cells were used as a negative control (‘‘uninfected’’). (A–B)
Percentage of wild-type (WT) (A) or DAA-resistant HCV (A156S) (B)-infected cells without treatment (mock) or in the presence of 25 mg/mL anti-HCV
IgG (nAb), 10 mg/mL anti-CLDN1 mAb or 1 mM telaprevir treatment as described in Figure 2 is shown. (C) The supernatant (SN) with or without anti-
HCV IgG containing cell-free wild-type or A156S HCV was used to infect fresh Huh7.5.1 cells. The cell culture medium was taken as a negative control.
The data are represented of three experiments.
doi:10.1371/journal.ppat.1004128.g003
Table 1. The CLDN1-specific antibody is efficient in inhibiting
HCV spread.
Treatment Percentage of HCV positive cells
mock 9662%
anti-CLDN1 1062%
telaprevir 2063%
daclatasvir 1563%
The spread assay was performed as shown in Figure 3 and Figure S3. The data
are pooled and represented as mean 6 SD form three experiments performed
in triplicate.
doi:10.1371/journal.ppat.1004128.t001
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cell culture models.
To assess whether prevention of resistance is universal to
HTEIs or compound-dependent, we performed side-by-side
experiments using a well- characterized SR-BI-specific mAb
NK-8H5-E3. This antibody has been shown to block efficiently
cell-free viral entry and viral dissemination in cell culture
models [8], Although the combination of this SR-BI-specific
mAb and simeprevir transiently decreased viral load and
delayed viral rebound, it did not result in viral clearance as
observed in CLDN1-specific mAb/simeprevir combination
therapy (Figure 5B). Sequence analysis in cells treated with
anti-SR-BI mAb and simeprevir revealed emergence of variants
conferring resistance to HCV protease inhibitors (NS3 Y56H)
[49] (data now shown) and to SR-BI inhibitors (N415D [39])
(Figure S6). Using direct sequencing we did not detect mutation
G451R [50], indicating that G451R is not emerging at high
frequency (Figure S6). These data indicate that distinct HTEIs
have different genetic barriers for antiviral resistance and that
the CLDN1-specific mAb OM-7D3-B3 used in this study
appears to have a higher genetic barrier than the SR-BI-specific
mAb NK-8H5-E3. This SR-BI-specific antibody was less
efficient in inhibiting HCV cell-cell transmission as compared
to the CLDN1-specific mAb (Figures S7 and S8), further
confirming that an efficient inhibition of HCV cell-cell
transmission appears to be required to prevent emergence of
DAA-resistant virus in cell culture models.
Finally, we also performed a long-term cell culture infection
assay investigating a combination of two DAAs on HCV infection.
We tested a highly potent NS5A inhibitor, daclatasvir, which has
been shown to have potent pan-genotypic activity against HCV
[51], first alone and then in combination with simeprevir in the
long-term HCV infection assay. In cell culture, a concentration of
0.1 nM has been shown to alter the subcellular localization and
biochemical fractionation of its target NS5A [52]. The concen-
tration of daclatasvir (5 nM) used in the experiment resulted in a
more than 10-fold decrease of viral load indicating that the dose is
below the IC90 in this experimental setting (Figure 5C). However,
during long-term treatment the viral load rebounded to the level of
the untreated cells at day 31 with emergence of the DAA-resistant
NS5A mutation, Y93H (Table 3). Furthermore, in contrast to the
combination of an HTEI and a protease inhibitor simeprevir, the
combination of daclatasvir and simeprevir (at concentrations .
IC90) failed to eradicate HCV genotype 2 infection in Huh7.5.1
cells and HCV load rebounded from day 45 on with emergence of
DAA-resistant mutations in both NS3 and NS5A regions
(Figure 5C and Table 3).
Taken together, these data indicate that blocking virus cell-cell
transmission by an HTEI prevents emergence of drug resistance to
DAAs.
Discussion
Although the development of DAAs has greatly improved the
outcome of chronic hepatitis C patients, viral resistance to DAAs is
still a challenge impeding treatment success. In this study, we
demonstrate that HCV strains which are resistant to DAAs
predominantly disseminate using cell-cell transmission and show
that effective blockade of cell-cell transmission using HTEIs
prevents viral resistance resulting in rapid virus elimination.
Figure 4. HTEIs effectively block cell-cell transmission of DAA-resistant viruses. The experimental setup is shown in Figure 1C. NS5A
+ HCV
producer cells (Pi) were transfected with HCV RNA encoding for HCV Jc1 NS3-A156S (A-B) or Jc1 NS3-L36M/R155K (C–D). NS5A+ HCV producer cells
and GFP-expressing target cells (T) were co-cultivated with nAb (anti-HCV IgG, 25 mg/mL) to block cell-free transmission as described [6]. Cell-cell
transmission of wild-type or drug-resistant strains was determined by quantification of GFP
+ NS5A
+ target cells (Ti) by flow cytometry. Protease or
NS5A inhibitor-resistant HCV variant producer cells (Pi) cultured with uninfected target cells (T) were then incubated with 1 mg/mL of CLDN1-specific
mAb or 10 mM of erlotinib or control medium. HCV-infected target cells (GFP
+NS5A
+) were quantified by flow cytometry (A and C). Percentage of
infected target cells is shown as histograms (B and D) and is represented as means 6 SD from three experiments performed in triplicate. *p,0.005.
doi:10.1371/journal.ppat.1004128.g004
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PLOS Pathogens | www.plospathogens.org 9 May 2014 | Volume 10 | Issue 5 | e1004128The ability of a virus to spread within a host is a key determinant
of its persistence and virulence.While cell-freeentry is important for
initiation of infection by virions entering the liver through the
bloodstream,HCVdisseminationwithinthe liver and establishment
of chronic HCV infection may mainly occur by direct cell-cell
transmission between adjacent hepatocytes [4]. Although differenc-
es in the abilityof diverse HCV genotypes to spreadvia cell-freeand
cell-cell transmission have been observed [3], cell-cell transmission
appears to serve as an important route of transmission for most
genotypes [3,12]. While cell-cell transmission has been shown to be
relevant for viral evasion from host neutralizing antibodies [6], our
data indicate that the spread of DAA-resistant HCV through cell-
cell transmission facilitates viral evasion and may contribute to
treatment failure. Blocking cell-cell transmission improves antiviral
activity of DAAs in cell culture models.
Functional results obtained in cell culture and animal models
demonstrate strong evidence that cell-cell transmission also plays
a relevant role in dissemination of several viruses including HIV,
herpes simplex virus (HSV), measles virus or human T-
lymphotropic virus type 1 (HTLV-1) [1,2]. Indeed, cell-cell
transmission has been described to spread resistance to antiret-
roviral drugs in HIV infection [53,54]. Discovery of a novel HBV
entry factor [55] will allow to investigate whether cell-cell
transmission plays a role in HBV transmission. Thus, this study
may provide a novel concept to prevent viral resistance in
treatment of other viruses.
By interfering with cell-cell transmission (Figure 4), HTEIs are
able to prevent the development of antiviral resistance as shown by
the absence of functional resistance in cells treated with a
combination of DAA and HTEI (Figure 5A). Most importantly,
when added to a DAA, an HTEI allowed rapid and efficient viral
clearance as shown by repeatedly confirmed absence of HCV
RNA using a highly sensitive and clinically licensed commercial
assay (Figure 5A). Since our data indicate that the main
transmission route of DAA-resistant variants is direct cell-cell
spread (Figure 2 and Figure 3), we assume that the preventive
effect of HTEIs is mainly due to their effect on this mode of
transmission. Taken together, these data indicate that blocking
viral cell-cell transmission enhances antiviral activity of DAAs and
prevents DAA-resistance in cell culture models as shown for HCV
genotype 2 infection as an example.
It has been discovered that cell-cell transmission of HIV is
resistant to DAAs and may lead to therapy failure [53]. Here,
we show that HCV cell-cell spread exists in the presence of
DAAs in cell culture models (Figure 3). Furthermore, our data
demonstrate evidence that HTEIs have differences in their
genetic barrier to resistance. Indeed, whereas treatment with
CLDN1-specific OM-7D3-B3 mAb resulted in viral clearance
without functional evidence for resistance (Figure 5A), SR-BI-
specific NK-8H5-E3 mAb resulted in the development of
resistant variants apparently escaping anti-SR-BI treatment
(Figure 5B). Resistance has been described for a small molecule
SR-BI antagonist [39]. Furthermore, a recent study elegantly
demonstrated that HCV can lose SR-BI-dependence for cell-
cell spread [10]. Together with the findings observed for SR-
BI-specific mAb NK-8H5-E3, our data demonstrate that
defined SR-BI-targeting compounds appear to have a lower
genetic barrier for resistance than other HTEIs such as
CLDN1-targeting compounds. This may be due to the fact
that CLDN1 is an essential factor for cell-cell transmission
Figure 5. Addition of HTEIs to DAA prevents the emergence of DAA-resistant variants. (A) Huh7.5.1 cells were transfected with RNA
encoding wild-type HCV Jc1 and plated in the presence of 1% DMSO and treated with anti-CLDN1 mAb (10 mg/mL), simeprevir (500 nM) alone or in
combination with anti-CLDN1 mAb (10 mg/mL) or in the absence of treatment (CTRL). The combination treatment was stopped on day 51 while anti-
CLDN1 mAb and simeprevir in monotherapy continued until day 58. Viral load was assessed by RT-PCR every 3–4 days. The limit of quantification
(LOQ), indicated by a dashed line, was 10
3 copies/mL. The experiment was performed in triplicate and repeated twice. Among the detected triplicate
samples, one out of three was HCV RNA negative on day 27 (empty circle under the LOQ), two out of three negative on day 30 (empty circles under
the LOQ), three out of three negative from day 37 on. The undetectable HCV load from day 40 was confirmed by a clinically licensed HCV RNA
detection assay, the Abbott RealTime HCV assay (Abbott), and is indicated by a star (LOD of Abbott qRT-PCR is 48 IU/mL with 250 mL liquid sample).
(B) A similarly designed experiment was performed using anti-SR-BI mAb NK-8H5-E3 instead of anti-CLDN1 mAb. (C) Combination of daclatasvir and
simeprevir fails to clear HCV genotype 2 infection. Using the same assay as described above, the cells were treated with 5 nM daclatasvir, 500 nM
simeprevir, combination of 5 nM daclatasvir and 500 nM simeprevir or mock (CTRL). Viral load was assessed by RT-PCR every 3–4 days. Means 6 SD
from a representative experiment performed in triplicate are shown.
doi:10.1371/journal.ppat.1004128.g005
Table 2. Absent toxicity in Huh7.5.1 cells treated with an HTEI and/or a DAA or 2 DAAs.
Treatment Treatment duration (days) Concentration Relative cell viability (%)
mock 60 N/A 10069
anti-CLDN1 60 10 mg/ml 12367
anti-SR-BI 60 10 mg/ml 9361
simeprevir 60 500 nM 9965
daclatasvir 50 5 nM 10268
anti-CLDN1+ simeprevir 60 10 mg/ml, 500 nM 13366
anti-SR-BI+ simeprevir 60 10 mg/ml, 500 nM 9269
daclatasvir + simeprevir 50 5 nM, 500 nM 107611
flavopiridol 3 10 mM2 0 66
Cytotoxic effect on Huh7.5.1 cells in the long-term HCV infection assay (Figure 5) were assessed by analyzing the ability to metabolize MTT as described in Materials and
Methods. 10 mM flavopiridol was used as a positive control. Data are presented as relative cell viability compared to cells cultured in the absence of compounds. Mean
6 SD from one representative experiment performed in triplicate are shown.
doi:10.1371/journal.ppat.1004128.t002
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Although accessory receptors CLDN6 and 9 have been
suggested to confer partial escape from CLDN1-targeting
agents for certain isolates in Huh7.5 cells [56], escape could
not be confirmed in primary human hepatocytes where
expression of CLDN6 and 9 is very low [57].
A theoretical drawback of using HTEIs instead of DAAs as
antivirals is their potential higher toxicity in vivo given these
molecules target host factors and not viral factors. Nevertheless, it
has to be pointed out that the development of several DAAs
targeting HCV proteins had to be stopped due to adverse effects
[5]. Moreover, it’s worth noting that the majority of current drugs
widely used for metabolic or inflammatory diseases or cancer,
targets host proteins [5]. The preliminary data obtained in this
study suggest that the combination of HTEIs and DAAs does not
result in detectable toxicity in cell-based assays (Table 2).
Furthermore, HTEIs targeting SR-BI or EGFR have been shown
to have an acceptable clinical safety profile in inflammatory
disease and cancer [58,59].
Collectively, our findings are not only relevant for the under-
standing of antiviral resistance but may also be of interest for the
development of future HCV therapies. For null or partial
responders and difficult-to-treat patients with co-morbidity or
defined genotypes, there is an unmet medical need for improved
antiviral regimens [20]. Compared to the various combinations of
DAAs of different classes which are currently evaluated in late stage
clinical development and expected to receive regulatory approval
soon, the combination of DAAs with an HTEI with a high genetic
barrier provides a novel strategy for prevention of antiviral
resistance in difficult-to-treat patients where viral breakthroughs
drive therapy failure [18,26] or future patients exhibiting multire-
sistance to various DAA combination therapies [18,26].
Indeed, this hypothesis is supported by our results of long-term
experiments in cell culture showing that the combination of an
HTEI and a DAA cured persistent HCV genotype 2a infection.
Since a similar NS3 protease/NS5A inhibitor DAA combination
failed to clear HCV genotype 2a and 2b infection in an HCV
animal model in vivo [60] and viral resistance has been observed for
DAAs in particular for genotype 2 and 3 in randomized clinical
trials (for review see[26]), our data suggest that the antiviral strategy
describedinthisstudymayaddresslimitationsofDAAsinparticular
for non-genotype 1 infections. Since our proof-of-concept study is
based on an HCV genotype 2a viral construct, future studies are
needed to investigate its relevance for other genotypes.
In this regard it is of interest to note that small molecule HTEIs
are currently investigated as monotherapy in randomized clinical
trials [61] (erlotinib: University of Strasbourg Hospitals, Clinical-
Trials.gov Identifier NCT01835938) and novel inhibitors of HCV
cell-cell transmission are also in preclinical development [62]. Our
study provides evidence and directions for their future application
in HCV treatment.
Finally, our results have implications for the treatment of other
viral infections. As targeting the host is an emerging strategy to
overcome resistance [63,64], blocking cell-cell transmission by
HTEIs provides a novel perspective for fighting a wide range of
viral infections including HIV, measles virus or HTLV-1 infection
where cell-cell transmission has been suggested to play a role in
transmission [1,2,53].
Accession numbers/ID numbers
The amino acid sequence of HCV polyprotein [recombinant
Hepatitis C virus J6/JFH1] has been previously deposited in
NCBI under access number AEB71614.1. The access numbers of
human CD81, CLDN1, SR-BI, OCLN, EGFR, HRas and IFN-a
Figure 6. Analysis of DAA-resistant mutations emerged during treatment protocols by direct sequencing. In the long-term HCV
infection assay shown in Figure 5A, HCV RNA in the supernatants from different treatments was purified on day 23. Direct sequencing was performed
to identify predominant viral mutations in HCV NS3 protease region as described in Materials and Methods. Data are displayed as NS3 amino acid
sequence in treated cells.
doi:10.1371/journal.ppat.1004128.g006
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AAB00195.1, AAB19486.2 and CAG47067.1 and AAA52724.1,
respectively. The nucleotide sequence of complete genome of
recombinant hepatitis C virus J6/JFH1 has been previously
deposited in GenBank under access number JF343793.1
Supporting Information
Figure S1 Functional characterization of protease in-
hibitor-resistant viruses in HCV infection and their
sensitivity to DAAs and HTEIs. Huh7.5.1 cells were pre-
Figure 7. Mutational analysis of viral variants with treatment of protease inhibitors or/and HTEIs in the long-term HCV infection
assay. Clonal sequencing of HCV NS3 mutations in simeprevir monotherapy and the combination of simeprevir and anti-CLDN1 mAb. To further
identify simeprevir induced DAA-resistance mutations, HCV RNA from (A) mock (CTRL), (B) 10 mg/mL anti-CLDN1 mAb, (C) 500 nM simeprevir or (D)
500 nM simeprevir +10 mg/mL anti-CLDN1 mAb treatment on day 23 as shown in Figure 5A and 6 was isolated and amplified as described in
Materials and Methods. Following cloning and sequencing of the NS3 protease region, the relative distribution of viral variants (wild-type (WT) and
NS3 mutations listed in a clockwise order beside the pie charts) was analyzed and is indicated in different shades of grey in the pie charts. The major
DAA-resistance mutation, D168V, is highlighted in blue and WT is in light grey. For each variant, the number of detected clones is indicated in the
parenthesis.
doi:10.1371/journal.ppat.1004128.g007
Table 3. Analysis of NS3A and NS5A mutations during DAA monotherapy or treatment with a combination of DAAs.
Treatment Treatment duration (days) NS3A sequence NS5A sequence
mock 31 WT WT
daclatasvir 31 WT Y93H
simeprevir 31 Q29H, D168A/V WT
simeprevir+ daclatasvir 45 L36V, E79A, Y56H, D168A/E/V C92S, Y93H
In the long-term HCV infection experiment shown in Figure 5C, HCV RNA in the supernatants from different treatments was purified on day 31 and day 45. Direct
sequencing was performed to identify predominant viral mutations in HCV NS3 and HCV NS5A regions as described in Materials and Methods.
doi:10.1371/journal.ppat.1004128.t003
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boceprevir, (C) CLDN1-specific mAb, (D) CD81-specific mAb, (E)
erlotinib, (F) SR-BI-specific mAb (NK-8H5-E3), (G) daclatasvir,
(H) CLDN1-specific mAb or respective control reagents before
incubation with HCVcc-Jc1-Luc containing the DAA-resistant
mutations NS3-A156S (A, C and E), NS3-R155K (B, D and F) or
NS5-Y93H (G and H), respectively in the presence of each
compound. HCV infection was analyzed 72 h post-infection by
luciferase reporter gene expression in cell lysates as described in
Materials and Methods. Means 6 standard error of the means
(SEM) from at least three independent experiments performed in
triplicate are shown.
(TIF)
Figure S2 Reduction of HCV load by the CLDN1-
specific antibody and daclatasvir in viral spread assay.
Daclatasvir (0.5 nM) or anti-CLDN1 mAb (10 mg/mL) was used
in HCV spread assay as described in Materials and Methods as
well as in Figure 2. The intracellular viral load was monitored by
measuring luciferase activity every 3–4 days. Means 6 SD from
one representative experiment performed in triplicate are shown.
(TIF)
Figure S3 Control of HCV spread by the CLDN1-
specific antibody and daclatasvir. As described in Materials
and Methods as well as in Figure 3, the relative percentage HCV-
positive cells/total cells at day 14 from the experiments shown in
Figure S2 was determined by immunostaining for NS5A and flow
cytometry. Uninfected Huh7.5.1 cells were used as a negative
control (‘‘uninfected’’) (A). Percentage of wild-type HCV-infected
cells without treatment (mock) (B) or in the presence of anti-
CLDN1 mAb (C) or daclatasvir (D) was shown. One representa-
tive experiment out of three independent experiments is shown.
(TIF)
Figure S4 Cell-cell transmission of NS5A inhibitor-
resistant viruses and effect of HTEIs. v1 mg/mL of
CLDN1-specific mAb or 10 mM of erlotinib was used in the cell-
cell transmission assay established with HCV RNA encoding for
HCV J4/JFH1 NS5A-Y93H as described inMaterials and Methods
as well as in Figure 4. (A) HCV-infected target cells (GFP
+NS5A
+)
were quantified by flow cytometry. (B) Percentage of infected target
cells is shown as histograms and is represented as means 6 SD from
three experiments performed in triplicate. *p,0.005.
(TIF)
Figure S5 Percentage of HCV-positive cells at the
initiation of treatment in the long-term HCV infection
assay. (A) The uninfected Huh7.5.1 cells were taken as a negative
control. (B) The relative percentage of HCV (Jc1)-positive cells/
total cells was determined as described in Materials and Methods
as well as in Figure 3.
(TIF)
Figure S6 Analysis of E1E2 mutations emerging during
treatment with the SR-BI-specific antibody. In Figure 5B,
HCV RNA in the supernatants from the SR-BI-specific antibody-
treated or mock-treated cells was purified on day 47. Direct
sequencing was performed to identify viral mutation(s) in HCV
E1E2 region and the sequence of Jc1 construct as described in
Materials and Methods. The sequence of HCV core, E1 and E2
was shown. Mutation N415D is indicated with a star.
(TIF)
Figure S7 The CLDN1-specific antibody is more effec-
tive than the SR-BI-specific antibody in controlling HCV
spread. Anti-CLDN1 mAb (10 mg/mL) or SR-BI mAb (10 mg/
mL) was used in the spread assay as described in Materials and
Methods as well as in Figure 2. The intracellular viral load was
monitored by measuring luciferase activity every 3–4 days. Means
6 SD from one representative experiment performed in triplicate
are shown.
(TIF)
Figure S8 The CLDN1-specific antibody is more effec-
tive than the SR-BI-specific antibody in inhibiting HCV
cell-cell transmission. Cell-cell transmission assay is described
in the Materials and Methods as well as in Figure 4. An anti-E2
human antibody (CBH-23) was used to stain HCV-positive cells in
the presence of anti-SR-BI mAb. (A) Rat or (B) mouse IgG was
used as control for (C) the CLDN1-specific antibody (10 mg/mL)
or (D) the SR-BI-specific antibody (10 mg/mL), respectively. (E)
Percentage of infected target cells is shown as histograms and is
represented as mean 6 SD from three experiments performed in
triplicate. *p,0.005.
(TIF)
Table S1 Functional characterization of DAA-resistant
viruses in HCV infection and their sensitivity to HTEIs.
In the experiment shown in Figure S1, IC50 was calculated. Means
6 SD from at least three independent experiments performed in
triplicate are shown.
(DOC)
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